Virpax Pharmaceuticals, Inc. VRPX

Full chart Compare
Set alert

Price alert · VRPX

All alert types
0.00 USD 0.00 (-62.50%)

At closeNov 2, 2026, 4:00 PM EST

0.45 +0.45 +149,833.33%

After hours · Nov 2, 4:00 PM ET

0.021 Day range 0.021
0.0001 52-week range 0.10
YTD
-97.30%
1 year
-98.57%

Financial health

Altman Z-Score

-90.71 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

0 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Valuation

P/E -0.1×
FY 2018: -3080×FY 2019: -248×FY 2020: -180×FY 2021: -82.7×FY 2022: -8.5×FY 2023: -6.2×FY 2024: -0.1×
FY 2018 5y median -8.5× FY 2024
P/S 0.0×
FY 2018: 0.0×FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×
FY 2018 5y median 0.0× FY 2024
P/B -44.2×
FY 2018: -6769×FY 2019: -312×FY 2020: -191×FY 2021: 26.8×FY 2022: 11.0×FY 2023: 48.4×FY 2024: -44.2×
FY 2018 5y median 11.0× FY 2024
P/FCF -0.0×
FY 2018: -4486×FY 2019: -752×FY 2020: -583×FY 2021: -69.1×FY 2022: -10.2×FY 2023: -9.5×FY 2024: -0.0×
FY 2018 5y median -10.2× FY 2024
EV/EBITDA -3.3×
FY 2018: 0.0×FY 2019: 0.0×FY 2020: 202202×FY 2021: 15543×FY 2022: -49.3×FY 2023: -37.6×FY 2024: -3.3×
FY 2018 5y median -3.3× FY 2024
EV/Sales 0.0×
FY 2018: 0.0×FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×
FY 2018 5y median 0.0× FY 2024
FCF Yield -41351.3%
FY 2018: -0.0%FY 2019: -0.1%FY 2020: -0.2%FY 2021: -1.4%FY 2022: -9.8%FY 2023: -10.5%FY 2024: -41351.3%
FY 2018 5y median -9.8% FY 2024

Profitability

Gross Margin 0.0%
FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%
FY 2018 5y median 0.0% FY 2024
Operating Margin 0.0%
FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%
FY 2018 5y median 0.0% FY 2024
Net Margin 0.0%
FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%
FY 2018 5y median 0.0% FY 2024
ROE 1320.6%
FY 2018: 221.4%FY 2019: 125.6%FY 2020: 106.4%FY 2021: -32.4%FY 2022: -129.4%FY 2023: -785.3%FY 2024: 1320.6%
FY 2018 5y median -32.4% FY 2024
ROIC 1322.0%
FY 2018: 379.1%FY 2019: 216.8%FY 2020: 158.3%FY 2021: -32.1%FY 2022: -131.8%FY 2023: -811.1%FY 2024: 1322.0%
FY 2018 5y median -32.1% FY 2024
ROA -775.7%
FY 2018: -4294.2%FY 2019: -7344.2%FY 2020: -964.2%FY 2021: -30.7%FY 2022: -109.1%FY 2023: -157.8%FY 2024: -775.7%
FY 2018 5y median -157.8% FY 2024

Growth (YoY)

Revenue 0.0%
FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%
FY 2018 FY 2024
Operating Income 23.0%
FY 2018: 0.0%FY 2019: -21.2%FY 2020: -31.9%FY 2021: -186.6%FY 2022: -81.7%FY 2023: 28.2%FY 2024: 23.0%
FY 2018 FY 2024
EPS (diluted) -446.7%
FY 2018: 0.0%FY 2019: -1141.5%FY 2020: -37.8%FY 2021: -14.3%FY 2022: -76.7%FY 2023: 29.2%FY 2024: -446.7%
FY 2018 FY 2024
Free Cash Flow -169509.2%
FY 2018: 0.0%FY 2019: 37.1%FY 2020: -22.4%FY 2021: -950.1%FY 2022: -22.7%FY 2023: 44.8%FY 2024: -169509.2%
FY 2018 FY 2024

Financial Health

Current Ratio 0.6×
FY 2018: 0.0×FY 2019: 0.0×FY 2020: 0.0×FY 2021: 19.0×FY 2022: 6.4×FY 2023: 1.3×FY 2024: 0.6×
FY 2018 5y median 1.3× FY 2024
Quick Ratio 0.6×
FY 2018: 0.0×FY 2019: 0.0×FY 2020: 0.0×FY 2021: 19.0×FY 2022: 6.4×FY 2023: 1.3×FY 2024: 0.6×
FY 2018 5y median 1.3× FY 2024
Debt / Equity 0.0×
FY 2018: -0.4×FY 2019: -0.5×FY 2020: -0.4×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×
FY 2018 5y median 0.0× FY 2024
Net Debt / EBITDA 0.1×
FY 2018: 0.0×FY 2019: 0.0×FY 2020: 378×FY 2021: -592×FY 2022: 5.7×FY 2023: 4.1×FY 2024: 0.1×
FY 2018 5y median 4.1× FY 2024
Interest Coverage -116×
FY 2018: -175×FY 2019: -25.5×FY 2020: -28.4×FY 2021: -130×FY 2022: 0.0×FY 2023: 0.0×FY 2024: -116×
FY 2018 5y median -28.4× FY 2024

Dividends

Dividend Yield 0.0%
FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%
FY 2018 5y median 0.0% FY 2024
Payout Ratio 0.0%
FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%
FY 2018 5y median 0.0% FY 2024

Annual · latest fiscal year ends 2024-12-31